Cancer therapy resistance: chasing epigenetics

Vakoc, C. R., Garcia-Manero, G., Look, A. T. (April 2014) Cancer therapy resistance: chasing epigenetics. Nature Medicine, 20 (4). pp. 340-341. ISSN 1078-8956

URL: http://www.ncbi.nlm.nih.gov/pubmed/24710376
DOI: 10.1038/nm.3528

Abstract

Resistance to targeted cancer therapies is a challenge to their successful application. T cell acute lymphoblastic leukemia (T-ALL) has been found to be associated with activation of the signaling protein NOTCH1; however, clinical success of NOTCH1-targeted therapies has been transient, probably owing to the development of drug resistance. Knoechel et al.1 now identify an epigenetic mechanism of drug resistance to NOTCH-targeted therapies in T-ALL cells. Furthermore, a combination therapy of NOTCH inhibitors and a drug targeting the epigenetic mechanism was found to be effective against the resistant cells. We asked three experts how this study is likely to affect the development of further cancer therapy programs.

Item Type: Paper
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies > chemoresistance
diseases & disorders > cancer > drugs and therapies
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > epigenetics
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > epigenetics
CSHL Authors:
Communities: CSHL labs > Vakoc lab
Depositing User: Matt Covey
Date: April 2014
Date Deposited: 15 May 2014 19:05
Last Modified: 15 May 2014 19:05
Related URLs:
URI: http://repository.cshl.edu/id/eprint/30137

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving